Covance Clinical Research Unit — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,412,910	1
2024	Research	$32,336	1
2022	Research	$21,569	1
2021	Research	$982,789	3
2020	Research	$219,867	1
2019	Research	$1,055,837	16

Breakdown

Who paid Research payments · program years 2019–2025

Biogen, Inc. $1,916,474 4 payments
Daiichi Sankyo Inc. $926,268 5 payments
Merck Sharp & Dohme Corporation $731,428 2 payments
Incyte Corporation $127,926 8 payments
Eli Lilly and Company $22,969 3 payments
Amgen Inc. $243 1 payment

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-Blind, Parallel-Group, Phase I Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of BIIB800 s.c. compared to the Reference Product Actemra® in Healthy Subjects $1,445,246 2 payments
A Phase 1 Study to Evaluate the Absorption, Distribution, Metabolism and Excretion of 14CMK-1026 in Healthy Participants. $731,428 2 payments
A Phase 1, Open-Label Study to Assess the Bioavailability of Gosuranemab (BIIB092) by Subcutaneous Injection in Healthy Participants $471,228 2 payments
Ds3201-A-U105 $455,062 3 payments
Ds3032-A-U107 $327,342 1 payment
Ds3032-A-U115 $143,864 1 payment
A Phase 1, Open Label Study to Evaluate the Pharmacokinetics and Safety of Itacitinib in Subjects with Normal Hepatic Function and Subjects with Varying Degrees of Hepatic Impairment $127,401 7 payments
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ly3372993 in Participants With Alzheimer's Disease $21,569 1 payment
A Randomized, Placebo-Controlled, Subject- and Investigator-Blind, Single and Multiple Dose, Safety, Tolerability, and Pharmacokinetics Study of Ly3463251 in Healthy and Overweight Healthy Subjects $900 1 payment
An Open Label, Dose Finding, and Cohort Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma $525 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.